stockrowBridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +55.8%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
Follow BBIO
Alert me
BridgeBio Pharma, Inc. (BBIO) Shares outstanding
BridgeBio Pharma, Inc.'s shares outstanding at the end of fiscal 2025 was $191.5M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $196.0M. Over the past ten years it has ranged from $30.6M (fiscal 2017) to $191.5M (fiscal 2025) — the current reading is the highest in ten years. BridgeBio Pharma, Inc. ranks 50th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $191.5M | 2.93% |
| FY2024 | $186.1M | 14.30% |
| FY2023 | $162.8M | 10.39% |
| FY2022 | $147.5M | 2.16% |
| FY2021 | $144.4M | 22.34% |
| FY2020 | $118.0M | 12.27% |
| FY2019 | $105.1M | 70.15% |
| FY2018 | $61.8M | 101.86% |
| FY2017 | $30.6M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $196.0M | 0.12% |
| Jun 2026 | $195.8M | 0.51% |
| Mar 2026 | $194.8M | 1.70% |
| Dec 2025 | $191.5M | (0.17%) |
| 28 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SMMT Summit Therapeutics PLC compare | $778.2M |
| EXEL Exelixis, Inc. compare | $255.8M |
| BBIO BridgeBio Pharma, Inc. | $196.0M |
| BMRN BioMarin Pharmaceutical Inc. compare | $193.6M |
| TECH Bio-Techne Corp compare | $157.0M |
| HALO Halozyme Therapeutics, Inc. compare | $122.6M |
| KYMR Kymera Therapeutics, Inc. compare | $100.1M |
| ASND Ascendis Pharma A/S compare | $68.3M |
| JAZZ Jazz Pharmaceuticals PLC compare | $64.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on BBIO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement